39.47 -0.02 (-0.05%)
After hours: 4:26PM EDT
|Bid||38.30 x 1100|
|Ask||39.80 x 4000|
|Day's Range||39.26 - 39.72|
|52 Week Range||31.99 - 40.16|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||37.43|
|Forward Dividend & Yield||1.40 (3.59%)|
|1y Target Est||41.66|
Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.
As discussed earlier, Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues. Novartis AG is the holding company providing healthcare solutions, and its business is classified into three business segments including the Innovative Medicines segment, Sandoz, and Alcon. The below chart shows the revenue performance of Novartis’s segments since the first quarter of 2017.
35 scientific data presentations and publications, including new evidence for LOKELMA™ in hyperkalemia and FARXIGA® on renal endpoi
60% of patients receiving LYNPARZA remained progression-free at three years compared to 27% on placebo following platinum-based chemotherapy
An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class. Given as a maintenance therapy to reinforce initial chemotherapy, Lynparza halted or reversed tumour growth in 60 percent of patients three years into the trial. At year four, the progression-free survival (PFS) rate in the Lynparza group was still above 50 percent, against 11 percent for chemotherapy alone.
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
Prime Minister Theresa May urged the EU on Monday not to allow a stand-off over a 'backstop' for Ireland to derail Brexit talks, saying she believed a deal was still achievable as a top EU official said chances of a no-deal divorce had increased. Addressing a rowdy session of parliament before she headed to Brussels for a summit on Wednesday, May remained upbeat but repeated she would not agree to anything that could split the United Kingdom.
AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.
AstraZeneca (AZN.L) will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.
Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.
Headquartered in Basel, Switzerland, Novartis (NVS) specializes in research and development, manufacturing, and marketing of a broad range of healthcare products. The company’s three segments are Innovative Medicines, Sandoz, and Alcon. Sandoz is Novartis’s generics business, and Alcon is its eye care business.